Morning Overview on MSN
A one-time gene edit safely lowered cholesterol in people for the first time
A single infusion of an experimental gene-editing therapy reduced LDL cholesterol in patients with familial ...
Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...
Morning Overview on MSN
A cholesterol-lowering shot also improved heart outcomes for high-risk diabetics, new data shows
Patients with diabetes and elevated cardiovascular risk but no prior heart attack or stroke saw fewer major cardiac events ...
Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...
The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by more than 50% among patients after a heart transplant, according to a late ...
Cardiovascular disease (CVD) remains the leading cause of death globally. Hypercholesterolemia is a major modifiable risk factor for developing atherosclerotic CVD (ASCVD). Although statins are the ...
PHILADELPHIA, PA—For high-risk patients with heterozygous familial hypercholesterolemia (HeFH), a novel therapy that shuts off the PCSK9 gene can lower LDL cholesterol, early data from the heart-1 ...
Conquering cholesterol is one of the biggest challenges facing cardiovascular disease patients, and a new study conducted by Amgen Inc. (AMGN 0.34%) shows that its cholesterol-busting drug Repatha may ...
Please provide your email address to receive an email when new articles are posted on . In heart transplant recipients, PCSK9 inhibitors lowered LDL, stabilized coronary intimal hyperplasia and were ...
The cholesterol-lowering medication alirocumab, a PCSK9 inhibitor, along with a statin, lowered LDL cholesterol levels more than 50% in patients after a heart transplant, compared to those taking a ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel target for low-density lipoprotein cholesterol (LDL-C)-lowering therapy, has been found to possess multiple off-target effects in humans.
In noting Q4 sales of Sanofi ($SNY) and Regeneron's ($REGN) brand-new PCSK9 med Praluent--€5 million, a far cry from analyst estimates of €41 million or more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results